Nicox: NCX 470 Shows Retinal Cell Protection in a Nonclinical Model

Nicox: NCX 470 Shows Retinal Cell Protection in a Nonclinical Model

September 30, 2021

Nicox, an international ophthalmology company, revealed additional data on NCX 470 in a nonclinical model of endothelin-1-induced retinal cell injury (ET-1). Nicox's lead clinical candidate, NCX 470, is a nitric oxide-donating prostaglandin analog in phase 3 clinical development for the treatment of open-angle glaucoma and ocular hypertension.

Glaucoma is mainly caused by an increase in intraocular pressure (IOP). However, a number of IOP-independent risk factors, including ischemia, add to damage to the optic nerve head and retina, resulting in visual loss.

NCX 470's potential protective effects on the retina and optic nerve head were investigated in exploratory nonclinical experiments published today.

The findings reveal that NCX 470 improves ocular perfusion and retinal function in damaged eyes when compared to vehicle, suggesting that it may have therapeutic properties over and above lowering of IOP.

Study Design and Results

Nonclinical experiments were performed to determine the effect of NCX 470 on ocular vascular reactivity and retinal function after repeated topical ocular dosing in a well-defined model of ischemia/reperfusion injury to the optic nerve in rabbits induced by ET-1.

ET-1 was administered twice-weekly for two weeks, then NCX 470 or vehicle was given concurrently for another four weeks.

Twice-weekly ET-1 dose increased ophthalmic artery resistivity after 2 weeks (P0.05 vs. baseline), and this continued to rise in the vehicle group for the next 4 weeks, reaching about 40% of baseline at week 6.

This detrimental effect was significantly reversed in eyes co-administered with NCX 470 0.1% twice daily (P<0.05 vs. vehicle at week 6).

Furthermore, ET-1 administration resulted in a significant decline in photoreceptor responses, which persisted in eyes treated with vehicle. The decline was almost completely reversed by week 6 in eyes treated with NCX 470. (p<0.05 vs. vehicle).

About Nicox S.A.

Headquartered in headquartered in Sophia Antipolis, France, Nicox S.A. is a global ophthalmology company that creates innovative solutions to help people maintain their vision and improve their ocular health.

In addition to Nicox’s lead program in clinical development, NCX 470, the company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.

Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE ® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.